Contact this trialFirst, we need to learn more about you.
PD-L1 Inhibitor
Durvalumab After Radiation for Stage 3 Lung Cancer
Recruiting1 awardPhase 2
Tacoma, Washington
This trial is testing a new cancer drug to see if it is effective in treating patients with Stage III lung cancer who are not eligible for chemotherapy. The trial will enroll patients into two groups depending on the dose of radiation therapy they have received.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.